Fidaxomicin demonstrates lower recurrence rates than vancomycin.

Findings indicate that fidaxomicin and vancomycin have no significant differences in overall treatment efficacy for Clostridium difficile infection (CDI). However, fidaxomicin significantly reduced recurrence rates at 40-day (RR=0.52), 60-day (RR=0.38), and 90-day (RR=0.62) intervals compared to vancomycin. Vancomycin was shown to be more effective for severe CDI cases. In terms of long-term mortality, fidaxomicin also performed better over 60 days (RR=0.57).